Neuroblastoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• MYCN 0
• AKT 0
• TP53 0
• ALK 3
• B7-H3 7
• ERK 0
• PI3K 0
• MAPK 1
• SNCA 0
• mTOR 0
• NRF2 0
• NRAS 0
• AMPK 0
• BCL-2 0
• EZH2 0
• JNK 0
• KRAS 0
• MYC 0
• PPAR 0
• STAT3 0
• STING 1
• CDK4/6 0
• NTRK 0
• RAS 1
• SIRT1 0
• CD19 3
• PARP 2
• TDP-43 0
• VEGF 1
• BDNF 0
• HDAC 0
• HMGB1 0
• ROS1 1
• YAP 0
• BRAF 0
• FAK 0
• HIF-1 0
• IL-1 0
• IL-15 3
• MEK 0
• NLRP3 0
• PINK1 0
• PTEN 0
• APP 0
• BACE1 0
• CD47 0
• CGRP 0
• EGFR 1
• FGFR 0
• GPX4 0
• IDH 1
• IL-6 0
• MAPT 0
• MDM2 0
• PD-1 0
• PD-L1 0
• RET 0
• SOD1 0
• TFEB 0
• TNF 0

16 of 16+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · K99

  Developing GFRA2 as an optimal immunotherapeutic target for neuroblastoma and Ewing sarcoma

  Children's Hosp of Philadelphia· Philadelphia, United States· US$109,364 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, United States· US$1,174,824 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors

  Mabswitch, Inc.· Van Nuys, United States· US$399,998 awarded in fiscal year 2026· until Aug 2027

• NIH NINDS · UG3

  Augmenting immunotherapy pharmacodynamics in glioma

  Mayo Clinic Rochester· Rochester, United States· US$712,838 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  Investigating the Molecular Effects of Social Deprivation on Neuroblastoma Tumorigenesis and Progression

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$558,294 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Phase I/II trial of an Oral ER-stress iNducer in relapsed/refractory neuroblastoma and paediatric solid tumours (PHOENIX)

  Fundacio Hospital Universitari Vall D'hebron - Institut de Recerca· Barcelona, Spain· EU contribution €8,468,780· until May 2032· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  CamoUflaged nanopaRticle-driven duAl Therapy to eradicate aggressIVe nEuroblastoma (CURATIVE)

  Universidad de Navarra· Pamplona, Spain· EU contribution €194,075· until May 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Engineered Nanomaterials as Adjuvants to Boost Neuroblastoma Vaccine Efficacy (NANO-ADJUVANT)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €268,569· until Apr 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €2,497,392· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  EURopean Epitranscriptomics of Cancer Academy (EURECA)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Netherlands· EU contribution €4,157,935· until Oct 2029· 8 countries

10 of 209 running projects, newest first. Listed amounts together: US$165.2m + €57.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  NCT02650401· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 5
• CRISPR-Cas Systems 5
• Gene Expression Profiling 45
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 4
• Proteomics 20
• Metabolomics 12
• Mass Spectrometry 10
• Flow Cytometry 19
• Immunohistochemistry 20
• Liquid Biopsy 3
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 21
• Machine Learning 12
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 5

• Enterovirus D68 B3 clade strains are efficiently recovered from cDNA infectious clones in 293T cells and infect human spinal cord organoids.

  J Virol, Apr 2026

• Organoid-Immune Co-Cultures: A Next-Generation approach to disease modeling.

  Mol Biol Rep, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.